Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare ...

William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a ...

On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...

On Monday, BMO Capital maintained its optimistic outlook on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), reiterating an Outperform rating with a $300.00 price target. The firm's confidence is ...

Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...